Salta al contenuto principale
notizia

Il laser a picosecondi PicoWay di Syneron Candela riceve l'approvazione della FDA per il trattamento delle lesioni pigmentate


Syneron Medical Ltd. (NASDAQ: ELOS), a global market leader in the aesthetic medical device marketplace, announced today that the PicoWay® picosecond laser received U.S. Food and Drug Administration (FDA) clearance for the treatment of pigmented lesions. The PicoWay picosecond laser previously received FDA clearance for the removal of tattoos in November 2014 and was launched in the U.S. late in the fourth quarter 2014.